Amritha Varshini Hanasoge Somasundara

Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms

R. Koche, R. Levine, S. Devlin, 2021, Clinical Cancer Research.

Amendment history : Corrigendum ( September 2018 ) JAK 2 / IDH-mutant – driven myeloproliferative neoplasm is sensitive to combined targeted inhibition

J. Teruya-Feldstein, Kwok-Kin Wong, M. V. Heiden, 2018 .

The molecular basis of mammary gland development and epithelial differentiation.

Camila O. dos Santos, Amritha Varshini Hanasoge Somasundara, P. F. Slepicka, 2020, Seminars in cell & developmental biology.

Targeting the CALR interactome in myeloproliferative neoplasms.

E. Pronier, A. Kentsis, R. Koche, 2018, JCI insight.

A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels

Ildikó V. Tóth, D. Rader, S. Kathiresan, 2017, Nature Medicine.

Loss of Function of GALNT2 Lowers High-Density Lipoproteins in Humans, Nonhuman Primates, and Rodents.

Christopher D. Brown, D. Rader, S. Kathiresan, 2016, Cell metabolism.

JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition

J. Teruya-Feldstein, Kwok-Kin Wong, M. V. Heiden, 2018, The Journal of clinical investigation.

JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition.

J. Teruya-Feldstein, K. Yen, M. V. Vander Heiden, 2018, The Journal of clinical investigation.